Charitable trust registration requires a specified-violation notice; settled cash deposits and related-party payments did not justify cancellation or ...
External development charges trigger TDS under section 194C, while disputed administrative payments require factual verification and fresh adjudicatio...
Section 270AA penalty immunity requires identified statutory defaults and a hearing before rejection; reassessment disclosure may constitute under-rep...
Section 80JJAA employee-cost deduction allowed for deployed staff but barred against transfer-pricing income enhancement, with pricing issues remanded...
Transfer-pricing methodology protects commercially genuine associated-enterprise payments, while pre-2016 secondary adjustments and related notional i...
Negative liens over operating assets can constitute international transactions requiring arm's-length pricing reflecting restricted borrowing and expa...
Cross-examination rights in Customs Broker revocation inquiries require witness examination; procedural denial may be cured through fresh adjudication...
DGFT amended SION A-222 under FTP-2023 regarding export norms for Erythromycin Stearate tablets. The revised norm establishes that for manufacturing one tablet of Erythromycin Stearate (250 mg), the permitted import quantity of Erythromycin Stearate is 334 mg. The amendment, effective immediately, allows pro-rata calculations for other product variants. This modification, executed under paragraphs 1.03 and 2.04 of FTP-2023, standardizes the input-output ratio for pharmaceutical manufacturers engaged in export of Erythromycin formulations, ensuring regulatory compliance and manufacturing consistency.
DGFT amended SION A-222 under FTP-2023 regarding export norms for Erythromycin Stearate tablets. The revised norm establishes that for manufacturing one tablet of Erythromycin Stearate (250 mg), the permitted import quantity of Erythromycin Stearate is 334 mg. The amendment, effective immediately, allows pro-rata calculations for other product variants. This modification, executed under paragraphs 1.03 and 2.04 of FTP-2023, standardizes the input-output ratio for pharmaceutical manufacturers engaged in export of Erythromycin formulations, ensuring regulatory compliance and manufacturing consistency.
Note: It is a system-generated summary and is for quick reference only.